Skip to main content
SpringerLink
Log in

Tolvaptan mindert die Progression bei ADPKD

Tolvaptan slows progression in ADPKD

  • Für Sie gelesen
  • Published:
Der Nephrologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bae KT, Zhu F, Chapman AB et al (2006) Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 1:64–69

    Article  PubMed  Google Scholar 

  2. Chang M-Y, Ong ACM (2012) Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract 120:c25–c34

    Article  PubMed  Google Scholar 

  3. Hogan MC, Masyuk TV, Page LJ et al (2010) Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21:1052–1061

    Article  PubMed  CAS  Google Scholar 

  4. Torres VE, Bankir L, Grantham JJ (2009) A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 4:1140–1150

    Article  PubMed  CAS  Google Scholar 

  5. Walz G, Budde K, Mannaa M et al (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363:830–840

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik Kinderheilkunde I, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Deutschland

    C. Betzen

Authors
  1. C. Betzen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Betzen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Betzen, C. Tolvaptan mindert die Progression bei ADPKD. Nephrologe 8, 65–66 (2013). https://doi.org/10.1007/s11560-012-0719-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-012-0719-7

Search

Navigation